Oxcarbazepine Tablet, Film Coated
Product Images NDC 0904-7595

This is a description of a medication package of Oxcarbazepine tablets in 600 mg dosage. The tablets are film-coated and contain FD&C Yellow No. 5 as a color additive. The package includes 100 tablets in a unit dose format. It is advised to refer to the product insert for dosage, prescribing information, precautions, and warnings. The package should be stored between 20%-25°C (77°F) with excursions allowed between 15°-30°C (58°-86°F). The medication should be dispensed in a tight container and kept out of children's reach as it is not child-resistant. This package is intended for institutional use only and is from NDC # 51991-055 by Breckenridge Pharmaceutical, Inc. Packaged and distributed by Major Pharmaceuticals in Indianapolis, USA.*

This is a prescription medication called Oxcarbazepine in tablet form, each containing 300 mg of the active ingredient. It is dispensed in unit dose packaging with 100 tablets per container. The tablets are film-coated and contain FD&C Yellow No. 5 as a color additive. Dispensing should include a medication guide, and dosage instructions can be found in the product insert. The drug is intended for institutional use only and should be stored in a tight container at controlled room temperature. The packaging is from Breckenridge Pharmaceutical, Inc., and distributed by Major Pharmaceuticals located in Indianapolis, USA.*

This text appears to be a label for Oxcarbazepine tablets, each containing 150 mg of the active ingredient. The tablets are film-coated and are dispensed in a quantity of 100 tablets (10 x 10). The medication includes FD&C Yellow No. 5 as a color additive. It provides information on dosage, storage conditions, and warnings. This product is intended for Institutional Use Only and is not child-resistant. The product is manufactured by Breckenridge Pharmaceutical, Inc. and distributed by Major Pharmaceuticals.*

This appears to be a description of a clinical trial evaluating the efficacy of Oxcarbazepine compared to Placebo. The log-rank test showed a statistically significant result with a p-value of 0.0001. The trial seems to have measured the exit rate across different days and time points, potentially showing the impact of treatment on patient outcomes. The data also includes information about the treatment group and the duration of the trial from Day 2 to Day 11.*

This text provides information about a study comparing the seizure rate between two groups receiving different treatments - Oxcarbazepine and Placebo. The log-rank test resulted in a p-value of 0.046, indicating a significant difference in seizure rates between the groups. The chart displays the days from the first dose to the first seizure for each group.*

This text provides data on the exit rate at different time intervals for two treatment groups categorized as HIGH and LOW. The exit rate is measured in days, with values ranging from 10 to 130. This information can be used to analyze the effectiveness of the treatments in relation to the time it takes for the subjects to exit.*

This text provides information on the exit rate at different time points for a treatment group with high and low values. The exit time in days is listed from 10 to 130, allowing for the evaluation of the effectiveness or outcomes of the treatment. This data can help analyze the progression or impact of the treatment over time.*